Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 1/2016

Open Access 01-02-2016 | Research Article

The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour

Authors: Stefanie Amarens de Boer, Joop Daniel Lefrandt, Japke Frida Petersen, Hendrikus Hessel Boersma, Douwe Johannes Mulder, Klaas Hoogenberg

Published in: International Journal of Clinical Pharmacy | Issue 1/2016

Login to get access

Abstract

Background Glucagon-like peptide-1 receptor agonists (GLP-1 RA) added to insulin in type 2 diabetes patients have shown to lower body weight, improve glycaemic control and reduce total daily insulin dose in short term studies, although the individual response greatly varies. Objective To evaluate GLP-1 RA treatment on body weight, glycaemic control and total daily insulin dose in obese, insulin-using type 2 diabetes patients after 2 years follow-up in a real life setting and to explore a possible relation with eating behaviour. Setting The Martini Hospital and the University Medical Center in Groningen in the Netherlands. Methods Eligible patients were at least 18 years of age, were on insulin therapy and obese (BMI > 30 kg/m2), started GLP-1 RA treatment. At baseline eating behaviour was classified according to the validated Dutch Eating Behaviour Questionnaire. A 2 years follow-up was performed. Main outcome measures Body weight, HbA1c and total daily insulin dose. Results 151 Patients started with exenatide or liraglutide. 120 patients completed the 2 years follow-up. From baseline to 2 years, body weight (mean ± SD) changed from 117.9 ± 22.1 to 107.9 ± 22.9 kg (P < 0.0001), HbA1c (median, IQR) changed from 7.9 (7.2–8.9) to 7.6 (6.9–8.3) % [63 (55–74) to 60 (52–67) mmol/mol] (P < 0.0001), total daily insulin dose changed from 90 (56–150) to 60 (0–100) Units/day (P < 0.0001). Weight change differed between eating behaviour groups (P < 0.001) in which external eating behaviour (n = 17) resulted in the smallest decline (−3.1 %) and restrained (n = 41) in the greatest (−10.3 %) in comparison with emotional (n = 37, −8.5 %) and indifferent (n = 25, −9.6 %) eating behaviours. Conclusion Two year of GLP-1 RA treatment resulted in a sustained reduction of weight, HbA1c and total daily insulin dose in obese, insulin-using type 2 diabetes patients in a real life setting. Largest weight loss was achieved in patients with a predominant restraint eating pattern while a predominant external eating pattern resulted in the smallest weight reduction.
Appendix
Available only for authorised users
Literature
1.
go back to reference Van Velsen EFS, Lamers J, Blok V, Van Leendert RJM, Kiewiet-Kemper RM. A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice. Neth J Med. 2014;72:523–7.PubMed Van Velsen EFS, Lamers J, Blok V, Van Leendert RJM, Kiewiet-Kemper RM. A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice. Neth J Med. 2014;72:523–7.PubMed
2.
go back to reference Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract. 2007;13:444–50.CrossRefPubMed Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract. 2007;13:444–50.CrossRefPubMed
3.
go back to reference Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM. Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM. 2010;103:687–94.CrossRefPubMed Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM. Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM. 2010;103:687–94.CrossRefPubMed
4.
go back to reference Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.CrossRefPubMedPubMedCentral Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.CrossRefPubMedPubMedCentral
5.
go back to reference Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.CrossRefPubMed Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.CrossRefPubMed
6.
go back to reference Goldenberg R. Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. Curr Med Res Opin. 2014;30:431–45.CrossRefPubMed Goldenberg R. Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. Curr Med Res Opin. 2014;30:431–45.CrossRefPubMed
7.
go back to reference Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384:2228–34.CrossRefPubMed Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384:2228–34.CrossRefPubMed
8.
go back to reference Rosenstock J, Shenouda SK, Bergenstal RM, Buse JB, Glass LC, Heilmann CR, et al. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care. 2012;35:955–8.CrossRefPubMedPubMedCentral Rosenstock J, Shenouda SK, Bergenstal RM, Buse JB, Glass LC, Heilmann CR, et al. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care. 2012;35:955–8.CrossRefPubMedPubMedCentral
9.
go back to reference Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824–30.CrossRefPubMed Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824–30.CrossRefPubMed
10.
go back to reference Van Bloemendaal L, IJzerman RG, Ten Kulve JS, Barkhof F, Konrad RJ, Drent ML, Veltman DJ, Diamant M. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63:4186–96.CrossRefPubMed Van Bloemendaal L, IJzerman RG, Ten Kulve JS, Barkhof F, Konrad RJ, Drent ML, Veltman DJ, Diamant M. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63:4186–96.CrossRefPubMed
11.
go back to reference Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002;110:43–52.CrossRefPubMedPubMedCentral Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002;110:43–52.CrossRefPubMedPubMedCentral
12.
go back to reference Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 1999;22:1137–43.CrossRefPubMed Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 1999;22:1137–43.CrossRefPubMed
13.
go back to reference Robert SA, Ghani RA, Zainuddin S, Shah SA, Mohamud WNW, Kamaruddin NA. The influence of a GLP-1 analogue, liraglutide on binge eating behavior among obese healthy participants. In: Data presented at: Annual Scientific Meeting of the Australian and New Zealand Obesity Society (ANZOS), Melbourne, Australia; Oct 17–19 2013. Robert SA, Ghani RA, Zainuddin S, Shah SA, Mohamud WNW, Kamaruddin NA. The influence of a GLP-1 analogue, liraglutide on binge eating behavior among obese healthy participants. In: Data presented at: Annual Scientific Meeting of the Australian and New Zealand Obesity Society (ANZOS), Melbourne, Australia; Oct 17–19 2013.
14.
go back to reference Herman CP, Polivy J. External cues in the control of food intake in humans: the sensory-normative distinction. Physiol Behav. 2008;94:722–8.CrossRefPubMed Herman CP, Polivy J. External cues in the control of food intake in humans: the sensory-normative distinction. Physiol Behav. 2008;94:722–8.CrossRefPubMed
15.
go back to reference Van Strien T, van der Zwaluw CS, Engels RC. Emotional eating in adolescents: a gene (SLC6A4/5-HTT)—depressive feelings interaction analysis. J Psychiatr Res. 2010;44:1035–42.CrossRefPubMed Van Strien T, van der Zwaluw CS, Engels RC. Emotional eating in adolescents: a gene (SLC6A4/5-HTT)—depressive feelings interaction analysis. J Psychiatr Res. 2010;44:1035–42.CrossRefPubMed
16.
17.
go back to reference Chaput JP, Leblanc C, Perusse L, Despres JP, Bouchard C, Tremblay A. Risk factors for adult overweight and obesity in the Quebec Family Study: Have we been barking up the wrong tree? Obesity (Silver Spring). 2009;17:1964–70.CrossRef Chaput JP, Leblanc C, Perusse L, Despres JP, Bouchard C, Tremblay A. Risk factors for adult overweight and obesity in the Quebec Family Study: Have we been barking up the wrong tree? Obesity (Silver Spring). 2009;17:1964–70.CrossRef
18.
go back to reference Van Strien T, Frijters J, Bergers G, Defares P. Nederlandse Vragenlijst voor eetgedrag (NVE). Handleiding [Dutch Eating Behavior Questionnaire Manual]. Lisse; 1986. Van Strien T, Frijters J, Bergers G, Defares P. Nederlandse Vragenlijst voor eetgedrag (NVE). Handleiding [Dutch Eating Behavior Questionnaire Manual]. Lisse; 1986.
19.
go back to reference Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47.CrossRefPubMed Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47.CrossRefPubMed
20.
go back to reference Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, et al. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol. 2012;11:107.CrossRefPubMedPubMedCentral Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, et al. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol. 2012;11:107.CrossRefPubMedPubMedCentral
21.
go back to reference Schlogl H, Kabisch S, Horstmann A, Lohmann G, Muller K, Lepsien J, et al. Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity. Diabetes Care. 2013;36:1933–40.CrossRefPubMedPubMedCentral Schlogl H, Kabisch S, Horstmann A, Lohmann G, Muller K, Lepsien J, et al. Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity. Diabetes Care. 2013;36:1933–40.CrossRefPubMedPubMedCentral
22.
go back to reference Banos RM, Cebolla A, Moragrega I, Van Strien T, Fernandez-Aranda F, Aguera Z, et al. Relationship between eating styles and temperament in an Anorexia Nervosa, Healthy Control, and Morbid Obesity female sample. Appetite. 2014;76:76–83.CrossRefPubMed Banos RM, Cebolla A, Moragrega I, Van Strien T, Fernandez-Aranda F, Aguera Z, et al. Relationship between eating styles and temperament in an Anorexia Nervosa, Healthy Control, and Morbid Obesity female sample. Appetite. 2014;76:76–83.CrossRefPubMed
23.
go back to reference Dossat AM, Bodell LP, Williams DL, Eckel LA, Keel PK. Preliminary examination of glucagon-like peptide-1 levels in women with purging disorder and bulimia nervosa. Int J Eat Disord. 2015;48:199–205.CrossRefPubMed Dossat AM, Bodell LP, Williams DL, Eckel LA, Keel PK. Preliminary examination of glucagon-like peptide-1 levels in women with purging disorder and bulimia nervosa. Int J Eat Disord. 2015;48:199–205.CrossRefPubMed
Metadata
Title
The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour
Authors
Stefanie Amarens de Boer
Joop Daniel Lefrandt
Japke Frida Petersen
Hendrikus Hessel Boersma
Douwe Johannes Mulder
Klaas Hoogenberg
Publication date
01-02-2016
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 1/2016
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-015-0219-8

Other articles of this Issue 1/2016

International Journal of Clinical Pharmacy 1/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.